Quarterly report pursuant to Section 13 or 15(d)

INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative)

v3.7.0.1
INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Oct. 01, 2015
Jul. 28, 2016
Jan. 26, 2016
Jun. 30, 2015
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Termination of licensing agreement         $ 132,804  
Agreement description               On March 31, 2016, the parties agreed to terminate the above described acquisition and to cancel any and all obligations assumed under the agreement.  
Intellectual property fees     $ 55,648            
Description for right to purchase perpetual rights     North America with the option for Central and South America for Naltrexone Implants formulas created by the Seller for 24 months upon receipt of the intellectual property for a fee of $55,648. The Company, within the first 12 months has the right to purchase perpetual rights for above territories for a one-time fee, financed over 5 years. The rights are amortized over the 24 month contract life.            
Amortization         $ 6,937   $ 13,797    
Common shares outstanding         242,136,285   242,136,285   181,804,501
Remaining deferred revenue         $ 768,743   $ 768,743   $ 1,046,264
Naltrexone Implant Formulation [Member]                  
Estimated useful life       10 years          
Aggregate purchase price       $ 1,132,000          
Purchase obligation to pay       $ 1,000,000          
Acquired rights, title and interest payment period 14 months                
Common shares outstanding       3,000,000          
Market value       $ 0.044          
Therakine, Ltd. [Member]                  
License cost   $ 2,750,000              
Aggregate purchase price   $ 250,000         $ 250,000   250,000
Escrow deposit                 $ 75,000
Therakine, Ltd. [Member] | Minimum [Member]                  
Sales of products   5.00%              
Therakine, Ltd. [Member] | Maximum [Member]                  
Sales of products   12.00%